News Release

May 18, 2021
JCR Pharmaceuticals Co., Ltd.

Translation

**JCR Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of JR-142, A long-acting growth hormone**

May. 18, 2021 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced today the dosing of the first patient in Phase 2 clinical trial of JR-142, a recombinant long-acting growth hormone on May 17, 2021 (JST). JCR is developing JR-142 to further enhance its growth hormone franchise, which is one of its core businesses.

In this study, a total of 24 pediatric subjects with growth hormone deficiency will be treated with JR-142 or GROWJECT® for 26 weeks to evaluate its efficacy, pharmacokinetic profile and safety. The summary of this study is registered on jRCT (Identifiier : jRCT2031200372).

Growth hormone replacement therapy normally requires administration via self-injections 6-7 times a week, administered by needle injection.
JR-142 has a significantly extended half-life in blood by fusing growth hormone with modified albumin, one of the JCR proprietary technologies, and is expected to exert an equivalent effect on growth with a once-per-week administration compared with existing daily administration products.

Currently, JCR is also developing a product for the treatment of short stature homeobox-containing gene (SHOX) deficiency (development code: JR-401X) as an expanded indication of its core product, GROWJECT®, a recombinant human growth hormone (Click here for related news release). JCR will continue to strive for the provision of various treatment options to meet the needs of patients suffering from growth disorders.

This announcement is expected to have a minor impact on JCR's consolidated financial results for the year ending on March 31, 2021.

**About JCR Pharmaceuticals Co., Ltd.**
JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 45-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder,

Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), Pompe disease, and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit https://www.jcrpharm.co.jp/en/site/en/.

***Cautionary Statement Regarding Forward-Looking Statements***

*This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as "believe," "estimate," "anticipate," "intend," "plan," "will," "would," "target" and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.*

*This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.*

*Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.*

Contact:
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jcrpharm.co.jp

###